Physician profile
Halyna Husak
NPI 1841908282
$2,034.70
in general payments reported to CMS, 2019-2025
21 companies · $709 in 2025
The $709 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $748 · 2024: $577 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.21 |
| Education | $187.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $316.28 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $267.88 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $222.74 | 2023-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $173.65 | 2023-2025 | |
| Incyte Corporation | $135.15 | 2023-2025 | Opzelura |
| Abbvie INC. | $125.37 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $105.45 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Leo Pharma INC. | $87.61 | 2023-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $76.51 | 2024-2025 | Tremfya, Simponi Aria, Simponi |
| Galderma Laboratories, L.P. | $70.90 | 2024-2025 | Aklief |
| Arcutis Biotherapeutics, INC. | $62.42 | 2024-2025 | Zoryve |
| Ucb, INC. | $59.04 | 2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $53.49 | 2024-2025 | Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $48.84 | 2024-2025 | Sotyktu |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $48.28 | 2023 | Vtama |
| Genzyme Corporation | $33.43 | 2023-2024 | |
| Revance Therapeutics, INC. | $17.06 | 2024 | Daxxify |
| Helsinn Therapeutics (U.S.), INC. | $14.62 | 2023 | Valchlor |
| Pfizer INC. | $13.44 | 2023 | |
| Organon LLC | $2.55 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halyna Husak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.